Q&A: Perry Nisen

Eric Bender

Nature, 2015, vol. 527, issue 7576, S18-S18

Abstract: A former paediatric oncologist and molecular biologist with experience in academia and industry, Perry Nisen was senior vice-president for science and innovation at GlaxoSmithKline in 2014 before becoming chief executive at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California. He discusses the challenges facing drug discovery in the era of big data.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/527S18a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:527:y:2015:i:7576:d:10.1038_527s18a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/527S18a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().